StockData
Silence Therapeutics plc logo

Silence Therapeutics plc (SLN) stock

SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/30
$19.80+0.00 (0.00%)

Close on Nov 17, 2026Market cap $935.48MP/E –Yield –

Silence Therapeutics cash

Cash and short-term investments held at the end of each period.

Silence Therapeutics's cash was $247.70M at Sep 30, 2026. For fiscal 2025 it was $85.10M, down 42.2% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$85.10M-42.2%
FY2024Dec 31, 2024$147.30M+114.1%
FY2023Dec 31, 2023$68.79M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$247.70M+142.4%
Q2 FY2026Jun 30, 2026$72.10M-36.9%
Q1 FY2026Mar 31, 2026$70.10M-48.6%
Q4 FY2025Dec 31, 2025$85.10M-42.2%
Q3 FY2025Sep 30, 2025$102.20M+48.6%
Q2 FY2025Jun 30, 2025$114.20M–
Q1 FY2025Mar 31, 2025$136.50M–
Q4 FY2024Dec 31, 2024$147.30M–
Q4 FY2023Dec 31, 2023$68.79M–

More Silence Therapeutics figures

See a number that looks wrong?